Oncoinvent ASA
ONCIN
Rank in Stocks
#24741
Oncoinvent ASA, a clinical-stage firm based in Oslo, Norway, is dedicated to... Oncoinvent ASA, a clinical-stage firm based in Oslo, Norway, is dedicated to developing innovative radiopharmaceutical treatments for various cancers. Its primary therapeutic agent is Radspherin, an alpha-emitting radiotherapeutic, which is currently undergoing investigation in two Phase 1/2a and one randomized Phase 2 clinical trials. This promising candidate is designed to target and treat malignancies that have metastasized to body cavities, specifically including the peritoneum.
Share Price
$6.89
Last synced: 2026-11-09
Market Cap
$30.86M
Change (1 day)
4.16%
Change (1 year)
8.54%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Oncoinvent ASA (ONCIN)
Category
Healthcare
Operating Margin for Oncoinvent ASA (ONCIN)
Operating Margin as of November 2026 TTM: -812.33%
According to Oncoinvent ASA's latest financial reports, its current operating margin (TTM) is -812.33%. At the end of 2025 the company had an operating margin of -615.20%.
Operating Margin history for Oncoinvent ASA from 2014 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -812.33% | 32.04% |
| 2025 | -615.20% | -96.55% |
| 2024 | -17,834.20% | -67.09% |
| 2023 | -54,186.16% | -31.03% |
| 2022 | -78,569.41% | 93.39% |
| 2021 | -40,628.42% | -6.48% |
| 2020 | -43,442.76% | 1,791.83% |
| 2019 | -2,296.34% | -72.44% |
| 2018 | -8,331.43% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | -100.00% |
| 2014 | -9,836.79% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.05% |
US
|
|
| -149.01% | -99.82% |
US
|
|
| 25.57% | -100.03% |
AU
|
|
| 31.23% | -100.04% |
BE
|
|
| 29.35% | -100.04% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Oncoinvent ASA's operating margin
What is Oncoinvent ASA's operating margin?
Oncoinvent ASA's operating margin is -812.33%, as of Nov 2026.
What was Oncoinvent ASA's operating margin in 2025?
In 2025, Oncoinvent ASA's operating margin was -615.20%, compared with -17,834.20% in 2024.
How has Oncoinvent ASA's operating margin changed since 2020?
From 2020 to 2025, Oncoinvent ASA's operating margin was highest in 2025 (-615.20%) and lowest in 2022 (-78,569.41%).
How does Oncoinvent ASA's operating margin compare with similar companies?
Oncoinvent ASA's operating margin (-812.33%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.